Clinical and translational research: 'Spotlight on breast cancer' one
New cancer research will help individualise treatment for patients with
New Advances In Breast Cancer Research And Treatment
(PDF) Recent Advances in the Treatment of Breast Cancer
8 Standard Tests in Breast Cancer Diagnosis
VIDEO
Breast cancer treatment side effects: Immunotherapy vs. chemotherapy
What is Neoadjuvant Therapy?
New study examines breast cancer treatment and aging
What Is The Cost Of Breast Cancer Treatment?
Interrupting Therapy to Attempt Pregnancy after Breast Cancer
Cancer Awareness
COMMENTS
What's New in Breast Cancer
Learn about new breast cancer treatment breakthroughs and recent developments in research that are fueling new ways to assess risk, prevent, detect and diagnose breast cancer.
Advances in Breast Cancer Research
This page highlights what's new and recent research in the detection and treatment of breast cancer. New methods to detect breast cancer, such as 3-D mammography, are described. Treatments tailored to breast cancer subtypes are discussed, including targeted therapies.
New study finds triple-negative breast cancer tumors with an increase
A new multicenter, international study suggests that people who have early-stage triple-negative breast cancer (TNBC) and high levels of immune cells within their tumors may have a lower risk of recurrence and better survival rates even when not treated with chemotherapy. The study was published today in the Journal of American Medical Association (JAMA).
Novel Drug Combination Shows Promise for Advanced HER2-Negative Breast
A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators from the Johns Hopkins Kimmel Cancer Center. The treatment included a histone deacetylase (HDAC) inhibitor — a drug that causes a chemical change to stop tumor cells from dividing — with two types of immunotherapy known as ...
Breast Cancer Treatments: Updates and New Challenges
This article reviews the latest advances and challenges in breast cancer treatments, such as immunotherapy, targeted therapy, and personalized medicine.
Strongest contender in decades in fight against breast cancer
This discovery represents the first advancement in hormonal treatment of ER+ breast cancer in decades and offers a promising new oral treatment strategy for the most prevalent form of breast cancer.
FDA Approves First Targeted Drug To Treat HER2-Low Breast Cancer
On August 5, 2022, the FDA approved the first targeted therapy for patients with HER2-low breast cancer that has spread to other parts of the body and is unable to be surgically removed. The drug, trastuzumab deruxtecan (T-DXd), was approved based on a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK) breast medical oncologist Shanu Modi.
Experimental immunotherapy targets metastatic breast cancer
An experimental form of immunotherapy that uses an individual's own tumor-fighting immune cells could potentially be used to treat people with metastatic breast cancer, according to results from an ongoing clinical trial led by researchers at the National Cancer Institute's (NCI) Center for Cancer Research, part of the National Institutes of Health. Many people with metastatic breast ...
Pembrolizumab for Advanced Triple-Negative Breast Cancer
New treatments needed for advanced triple-negative breast cancer Triple-negative breast cancer tends to be more aggressive, harder to treat, and more likely to recur than other forms of the disease, such as hormone receptor -positive or HER2 -positive breast cancers.
Targeting HER2-positive breast cancer: advances and future directions
The discovery of the monoclonal antibody trastuzumab almost 25 years ago revolutionized treatment and drug development for HER2+ breast cancer. Here, Swain et al. review the current standard of ...
Breast Cancer Drug Trial Results in 'Unheard-Of' Survival
The patients had metastatic breast cancer that had been progressing despite rounds of harsh chemotherapy. But a treatment with a drug that targeted cancer cells with laserlike precision was ...
Breast cancer metastasis on/off switch revealed
New research from Stanford and the Arc Institute could lead to a new and more effective immunotherapy and help clinicians better predict patient response to existing medicines.
What's New in Breast Cancer Research?
What's New in Breast Cancer Research? Researchers around the world are working to find better ways to prevent, detect, and treat breast cancer, and to improve the quality of life of patients and survivors.
New Therapy for Advanced Breast Cancer Has Roots in Duke Lab
On January 27, 2023, the Food and Drug Administration approved a new targeted therapy for hard-to-treat advanced breast cancers. Its development was made possible by research and advocacy from the lab of Donald McDonnell, PhD, in the Department of Pharmacology and Cancer Biology.
Management of patients with advanced-stage HER2-positive breast cancer
The implementation of novel and effective treatments for metastatic HER2-positive (HER2 +) breast cancer has challenged the assumption that this is an incurable disease, posing new research and ...
Immunotherapy in breast cancer: an overview of current ...
In triple-negative breast cancer, the combination of cancer immunotherapy based on PD-1/PD-L1 immune checkpoint inhibitors with chemotherapy was effective both in advanced and early setting phase ...
Our top 5 research breakthroughs of 2023
A new way to boost breast cancer treatment. In early 2023, our researchers found a way to potentially improve treatment effectiveness, by targeting a different form of a common protein. Dr Ahmet Ucar and this team from the University of Manchester found that a protein called RAC1B can help the disease become resistant to treatment, spread and ...
New and Emerging Targeted Therapies for Advanced Breast Cancer
New emerging technologies are on the horizon for the treatment of breast cancer, including immuno-oncolytic virus drugs, histone deacetylase inhibitors, and novel combination therapies [9, 10, 11]. In this review, we will discuss the most novel breast cancer treatments for HER2-positive, HER2-negative, and triple-negative breast cancers, and ...
Breast Cancer: An Overview of Current Therapeutic Strategies, Challenge
Breast Cancer: An Overview of Current Therapeutic Strategies, Challenge, and Perspectives. Breast cancer is the most commonly diagnosed cancer and the leading cause of death among female patients, which seriously threatens the health of women in the whole world. The treatments of breast cancer require the cooperation of a multidisciplinary ...
Combo Treatment With New Breast Cancer Drugs Is Promising
The Challenge About 10% to 15% of people diagnosed with breast cancer have the triple-negative subtype. There are few FDA-approved targeted therapies to treat triple-negative breast cancer (TNBC), and even after treatment, almost half of people with TNBC have a recurrence within 3 years. Development of new treatment strategies for this deadly cancer is crucial.
New targeted treatment for early breast cancer could reduce risk of
The new drug combination will be available to adults with hormone receptor-positive, HER-2 negative, node positive breast cancer, on the NHS in England. The targeted drug has been recommended alongside hormone therapy as a treatment option to reduce the risk of cancer returning after surgery.
Single-Cell RNA-Sequencing: Opening New Horizons for Breast Cancer Research
Breast cancer is the most prevalent malignant tumor among women with high heterogeneity. Traditional techniques frequently struggle to comprehensively capture the intricacy and variety of cellular states and interactions within breast cancer. As global precision medicine rapidly advances, single-cell RNA sequencing (scRNA-seq) has become a highly effective technique, revolutionizing breast ...
Precision therapeutics and emerging strategies for HR-positive ...
In this Review, we describe the evolving treatment paradigm for patients with metastatic HR + breast cancer in light of the growing armamentarium of drugs and biomarkers that will help to shape the future therapeutic landscape. These strategies are expected to involve tumour molecular profiling to enable the delivery of precision medicine.
Combination of Existing Drugs Could Improve Breast Cancer Therapy
"This is a serious gap in treatment, and new medicines are needed." Solid tumors — like triple-negative breast cancers, known as TNBC, and mesothelioma, cancer that forms in the internal organs — are often not responsive to chemotherapy or certain immune therapies, such as checkpoint inhibitors, which are drugs that block checkpoint ...
Home
Breast Cancer Research and Treatment is a comprehensive forum dedicated to all aspects of breast cancer research. The journal's focus spans across various disciplines including surgery, radiotherapy, medical oncology, endocrinology, epidemiology, immunology and cell biology. Provides an international platform for the discussion and resolution ...
The treatment landscape of triple-negative breast cancer
According to Cancer Statistics 2023 by the American Cancer Society, breast cancer (BC) incidence continued to increase, accounting for 31% of female cancers at the top of ten leading cancer types for the estimated new cancer cases [].Triple-negative breast cancer (TNBC) tumors are biologically aggressive BC, describing 15-20% of BC, which are estrogen receptor (ER), progesterone receptor ...
Lab-grown stem cells could be a 'breakthrough' for cancer treatment
Human blood stem cells have been made in a laboratory for the first time, which could significantly improve how we treat certain types of cancer.. The lab-grown cells have so far only been tested ...
Application of Nanomaterials in the Diagnosis and Treatment of Breast
Breast cancer, the most prevalent malignancy among women globally, poses a significant threat to women's health. With over 2.3 million new cases and 670,000 deaths in 2022, advancements in treatment are urgently needed. Traditional therapies, including surgery, radiotherapy, and chemotherapy, have shown promise but face challenges due to tumor heterogeneity and drug resistance. Additionally ...
Surprise Discovery: Scientists Discover New Anti-Cancer ...
In the past, cancer was usually a death sentence, but research has made considerable progress in recent decades and has significantly increased the survival time with a high quality of life for many types of cancer. Recently, adoptive T-cell therapy in particular has developed into an effective treatment tool.
Elle Macpherson's Secret Cancer Diagnosis Saw Her Refuse ...
The businesswoman was diagnosed with HER2-positive estrogen-receptive intraductal cancer seven years ago following a lumpectomy. A lumpectomy is a surgical procedure that removes a breast tumor ...
IMAGES
VIDEO
COMMENTS
Learn about new breast cancer treatment breakthroughs and recent developments in research that are fueling new ways to assess risk, prevent, detect and diagnose breast cancer.
This page highlights what's new and recent research in the detection and treatment of breast cancer. New methods to detect breast cancer, such as 3-D mammography, are described. Treatments tailored to breast cancer subtypes are discussed, including targeted therapies.
A new multicenter, international study suggests that people who have early-stage triple-negative breast cancer (TNBC) and high levels of immune cells within their tumors may have a lower risk of recurrence and better survival rates even when not treated with chemotherapy. The study was published today in the Journal of American Medical Association (JAMA).
A novel three-drug combination achieved notable responses in patients with advanced HER2-negative breast cancer, according to new research directed by investigators from the Johns Hopkins Kimmel Cancer Center. The treatment included a histone deacetylase (HDAC) inhibitor — a drug that causes a chemical change to stop tumor cells from dividing — with two types of immunotherapy known as ...
This article reviews the latest advances and challenges in breast cancer treatments, such as immunotherapy, targeted therapy, and personalized medicine.
This discovery represents the first advancement in hormonal treatment of ER+ breast cancer in decades and offers a promising new oral treatment strategy for the most prevalent form of breast cancer.
On August 5, 2022, the FDA approved the first targeted therapy for patients with HER2-low breast cancer that has spread to other parts of the body and is unable to be surgically removed. The drug, trastuzumab deruxtecan (T-DXd), was approved based on a clinical trial led by Memorial Sloan Kettering Cancer Center (MSK) breast medical oncologist Shanu Modi.
An experimental form of immunotherapy that uses an individual's own tumor-fighting immune cells could potentially be used to treat people with metastatic breast cancer, according to results from an ongoing clinical trial led by researchers at the National Cancer Institute's (NCI) Center for Cancer Research, part of the National Institutes of Health. Many people with metastatic breast ...
New treatments needed for advanced triple-negative breast cancer Triple-negative breast cancer tends to be more aggressive, harder to treat, and more likely to recur than other forms of the disease, such as hormone receptor -positive or HER2 -positive breast cancers.
The discovery of the monoclonal antibody trastuzumab almost 25 years ago revolutionized treatment and drug development for HER2+ breast cancer. Here, Swain et al. review the current standard of ...
The patients had metastatic breast cancer that had been progressing despite rounds of harsh chemotherapy. But a treatment with a drug that targeted cancer cells with laserlike precision was ...
New research from Stanford and the Arc Institute could lead to a new and more effective immunotherapy and help clinicians better predict patient response to existing medicines.
What's New in Breast Cancer Research? Researchers around the world are working to find better ways to prevent, detect, and treat breast cancer, and to improve the quality of life of patients and survivors.
On January 27, 2023, the Food and Drug Administration approved a new targeted therapy for hard-to-treat advanced breast cancers. Its development was made possible by research and advocacy from the lab of Donald McDonnell, PhD, in the Department of Pharmacology and Cancer Biology.
The implementation of novel and effective treatments for metastatic HER2-positive (HER2 +) breast cancer has challenged the assumption that this is an incurable disease, posing new research and ...
In triple-negative breast cancer, the combination of cancer immunotherapy based on PD-1/PD-L1 immune checkpoint inhibitors with chemotherapy was effective both in advanced and early setting phase ...
A new way to boost breast cancer treatment. In early 2023, our researchers found a way to potentially improve treatment effectiveness, by targeting a different form of a common protein. Dr Ahmet Ucar and this team from the University of Manchester found that a protein called RAC1B can help the disease become resistant to treatment, spread and ...
New emerging technologies are on the horizon for the treatment of breast cancer, including immuno-oncolytic virus drugs, histone deacetylase inhibitors, and novel combination therapies [9, 10, 11]. In this review, we will discuss the most novel breast cancer treatments for HER2-positive, HER2-negative, and triple-negative breast cancers, and ...
Breast Cancer: An Overview of Current Therapeutic Strategies, Challenge, and Perspectives. Breast cancer is the most commonly diagnosed cancer and the leading cause of death among female patients, which seriously threatens the health of women in the whole world. The treatments of breast cancer require the cooperation of a multidisciplinary ...
The Challenge About 10% to 15% of people diagnosed with breast cancer have the triple-negative subtype. There are few FDA-approved targeted therapies to treat triple-negative breast cancer (TNBC), and even after treatment, almost half of people with TNBC have a recurrence within 3 years. Development of new treatment strategies for this deadly cancer is crucial.
The new drug combination will be available to adults with hormone receptor-positive, HER-2 negative, node positive breast cancer, on the NHS in England. The targeted drug has been recommended alongside hormone therapy as a treatment option to reduce the risk of cancer returning after surgery.
Breast cancer is the most prevalent malignant tumor among women with high heterogeneity. Traditional techniques frequently struggle to comprehensively capture the intricacy and variety of cellular states and interactions within breast cancer. As global precision medicine rapidly advances, single-cell RNA sequencing (scRNA-seq) has become a highly effective technique, revolutionizing breast ...
In this Review, we describe the evolving treatment paradigm for patients with metastatic HR + breast cancer in light of the growing armamentarium of drugs and biomarkers that will help to shape the future therapeutic landscape. These strategies are expected to involve tumour molecular profiling to enable the delivery of precision medicine.
"This is a serious gap in treatment, and new medicines are needed." Solid tumors — like triple-negative breast cancers, known as TNBC, and mesothelioma, cancer that forms in the internal organs — are often not responsive to chemotherapy or certain immune therapies, such as checkpoint inhibitors, which are drugs that block checkpoint ...
Breast Cancer Research and Treatment is a comprehensive forum dedicated to all aspects of breast cancer research. The journal's focus spans across various disciplines including surgery, radiotherapy, medical oncology, endocrinology, epidemiology, immunology and cell biology. Provides an international platform for the discussion and resolution ...
According to Cancer Statistics 2023 by the American Cancer Society, breast cancer (BC) incidence continued to increase, accounting for 31% of female cancers at the top of ten leading cancer types for the estimated new cancer cases [].Triple-negative breast cancer (TNBC) tumors are biologically aggressive BC, describing 15-20% of BC, which are estrogen receptor (ER), progesterone receptor ...
Human blood stem cells have been made in a laboratory for the first time, which could significantly improve how we treat certain types of cancer.. The lab-grown cells have so far only been tested ...
Breast cancer, the most prevalent malignancy among women globally, poses a significant threat to women's health. With over 2.3 million new cases and 670,000 deaths in 2022, advancements in treatment are urgently needed. Traditional therapies, including surgery, radiotherapy, and chemotherapy, have shown promise but face challenges due to tumor heterogeneity and drug resistance. Additionally ...
In the past, cancer was usually a death sentence, but research has made considerable progress in recent decades and has significantly increased the survival time with a high quality of life for many types of cancer. Recently, adoptive T-cell therapy in particular has developed into an effective treatment tool.
The businesswoman was diagnosed with HER2-positive estrogen-receptive intraductal cancer seven years ago following a lumpectomy. A lumpectomy is a surgical procedure that removes a breast tumor ...